Abstract
Background By March 2021, South Africa experienced two waves of SARS-CoV-2 infections; the second associated with emergence of Beta variant. We estimated the burden and transmission of SARS-CoV-2 over the two waves.
Methods We conducted a prospective cohort study during July 2020-March 2021 in one rural and one urban community. Mid-turbinate nasal swabs were collected twice-weekly from consenting household members irrespective of symptoms and tested for SARS-CoV-2 using real-time reverse transcription polymerase chain reaction (rRT-PCR). Serum was collected every two months and tested for anti-SARS-CoV-2 antibodies. Household cumulative infection risk (HCIR) was defined as the proportion of household members with infection following SARS-CoV-2 introduction.
Findings Among 71,759 nasal specimens from 1,189 members (follow-up rate 93%), 834 (1%) were SARS-CoV-2-positive. By PCR detection and serology combined, 34% (406/1189) of individuals experienced ≥1 SARS-CoV-2 infection episode, and 3% (12/406) experienced reinfection. Infection by PCR and/or serology before the second wave was 84% (95% confidence interval (CI) 65%-93%) protective against re-infection. Of 254 PCR-confirmed episodes with available data, 17% (n=43) were associated with ≥1 symptom, of which 21% (9/43) were medically attended. Among 222 included households, 161 (73%) had ≥1 SARS-CoV-2-positive individual. HCIR was 16% (66/411). On multivariable analysis, index case lower cycle threshold value (OR 5.8, 95% CI 1.8-19.1), urban community (OR 3.1, 95% CI 1.5-6.2) and infection with Beta variant (OR 3.7, 95% CI 1.6-8.4) were associated with increased HCIR. HCIR was similar for symptomatic (8/67,12%) and asymptomatic (61/373, 16%) index cases (p-0.302).
Interpretation In this study, 83% of SARS-CoV-2 infections were asymptomatic and index case symptom status did not affect HCIR, suggesting a limited role for control measures targeting symptomatic individuals. Previous infection was protective against SARS-CoV-2 infection in the second wave although household transmission increased following the emergence of Beta variant.
Funding US Centers for Disease Control and Prevention
Evidence before this study Previous studies have generated wide-ranging estimates of the proportion of SARS-CoV-2 infections which are asymptomatic. A recent systematic review found that 20% (95% CI 3%-67%) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remained asymptomatic throughout infection and that transmission was lower from asymptomatic individuals.1 A systematic review and meta-analysis of 54 household transmission studies of SARS-CoV-2 found an estimated secondary attack rate of 17% (95% CI 14-19).2 The review also found that household secondary attack rates were increased from symptomatic index cases and that adults were more likely to acquire infection. South Africa experienced two waves of SARS-CoV-2 infections; the second wave was larger and associated with emergence of 501Y.V2 lineage. Modelling studies have suggested that SARS-CoV-2 variant 501Y.V2 may be more transmissible than other variants or that past exposure may provide limited protection, however, they were not able to establish which of these may be more important. A community study from Denmark and two healthcare worker cohorts estimated protection conferred by previous SARS-CoV-2 infection against reinfection to be between 81% and 89%. Data on protection conferred against infection with the 501Y.V2 variant are limited. Studies to quantify the burden of asymptomatic infections, symptomatic fraction, duration of shedding and household transmission of SARS-CoV-2 from asymptomatically infected individuals have mostly been conducted as part of outbreak investigations or in specific settings. Comprehensive systematic community studies and studies of 501Y.V2 are lacking.
Added value of this study We found that from the start of the SARS-CoV-2 pandemic in March 2020 through March 2021 in South Africa, 406 (34%) of 1189 individuals from 222 randomly sampled households in a rural and an urban community in South Africa had at least one confirmed SARS-CoV-2 infection, detected on rRT-PCR- and/or serology, and 3% (12/406) experienced reinfection. Individuals with evidence of infection identified by PCR and/or serology before the onset of the second wave (14 December 2020) experienced 84% (95% CI 65%-93%) protection against re-infection compared to individuals without evidence of previous infection. Symptom data were analysed for 254 rRT-PCR-confirmed infection episodes that occurred >14 days after the start of follow-up (of a total of 310 episodes), of these, 17% (n=43) were associated with one or more symptom, of which 14% (n=6) were hospitalised and 2% (n=1) died. Seventy three percent (161/222) of included households, had one or more individual infected with SARS-CoV-2 within the household. SARS-CoV-2 infected index cases transmitted the infection to 16% (66/411) of susceptible household contacts. Index case ribonucleic acid (RNA) viral load estimated through cycle threshold value as proxy was strongly predictive of household transmission. Index case or household contact age group and presence of symptoms in the index case were not associated with household transmission. Household transmission was four times greater from index cases infected with Beta variant compared to non-variant infection.
Implications of all the available evidence We found a high rate of SARS-CoV-2 infection in households in a rural community and an urban community in South Africa, with the majority of infections being asymptomatic in individuals of all ages. The household cumulative infection risk was 16% and did not differ by index case or contact age or presence of symptoms but was higher in households where the index case had potentially higher viral RNA and during the second wave of SARS-CoV-2 infection. The majority of infections were asymptomatic. Asymptomatic individuals transmitted SARS-CoV-2 at similar levels to symptomatic individuals suggesting that interventions targeting symptomatic individuals such as contact tracing of individuals tested because they report symptoms may have a limited impact as a control measure. The high level of heterologous protection from natural immunity evidenced in our study also informs our understanding of possible effects of population-level immunity on SARS-CoV-2 burden and transmission, although key questions remain regarding the durability of protection in the face of continued viral evolution.
Competing Interest Statement
CC has received grant support from Sanofi Pasteur, Advanced Vaccine Initiative, and payment of travel costs from Parexel. AvG has received grant support from Sanofi Pasteur, Pfizer related to pneumococcal vaccine, CDC and the Bill & Melinda Gates Foundation. NW report grants from Sanofi Pasteur and the Bill & Melinda Gates Foundation. NAM has received a grant to his institution from Pfizer to conduct research in patients with pneumonia and from Roche to collect specimens to assess a novel TB assay.
Clinical Trial
NCT02519803
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT02519803
Funding Statement
This work was supported by the National Institute for Communicable Diseases of the National Health Laboratory Service and the U.S. Centers for Disease Control and Prevention [co-operative agreement number: 6 U01IP001048-04-02].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PHIRST-C protocol was approved by the University of Witwatersrand Human Research Ethics Committee (Reference 150808) and the U.S. Centers for Disease Control and Preventions Institutional Review Board relied on the local review (#6840). The protocol was registered on clinicaltrials.gov on 6 August 2015 and updated on 30 December 2020 (https://clinicaltrials.gov/ct2/show/NCT02519803). Participants receive grocery store vouchers of ZAR50 (USD 3) per visit to compensate for time required for specimen collection and interview.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The investigators welcome enquiries about possible collaborations and requests for access to the data set. Data will be shared after approval of a proposal and with a signed data access agreement. Investigators interested in more details about this study, or in accessing these resources, should contact the principle investigator, Prof Cheryl Cohen, at NICD (cherylc{at}nicd.ac.za).
